<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tolterodine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tolterodine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tolterodine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11105" href="/d/html/11105.html" rel="external">see "Tolterodine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13073" href="/d/html/13073.html" rel="external">see "Tolterodine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F230065"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Detrol;</li>
<li>Detrol LA</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868470"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Tolterodine [DSC];</li>
<li>Detrol;</li>
<li>Detrol LA;</li>
<li>JAMP-Tolterodine;</li>
<li>MINT-Tolterodine;</li>
<li>MYLAN-Tolterodine ER [DSC];</li>
<li>SANDOZ Tolterodine LA;</li>
<li>TEVA-Tolterodine;</li>
<li>TEVA-Tolterodine LA</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F230100"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F230070"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b535f21f-0bb0-4bcf-a157-b23810b32dff">Treatment of overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Treatment of overactive bladder:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release tablet:</i> 2 mg twice daily; the dose may be lowered to 1 mg twice daily based on individual response and tolerability</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release capsule:</i> 4 mg once daily; dose may be lowered to 2 mg once daily based on individual response and tolerability</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991584"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Immediate release tablet:</i> Significantly reduced renal function (studies conducted in patients with CrCl 10 to 30 mL/minute): 1 mg twice daily; use with caution</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Extended release capsule:</i></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 30 mL/minute: 2 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Use is not recommended; has not been studied.</p></div>
<div class="block doha drugH1Div" id="F50988766"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Immediate release tablet:</i> Significantly reduced hepatic function: 1 mg twice daily; use with caution</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Extended release capsule:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A or B): 2 mg once daily</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Use is not recommended; has not been studied.</p></div>
<div class="block adr drugH1Div" id="F230037"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported with immediate release tablet, unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Xerostomia (35%; extended release capsules: 23%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (7%; extended release capsules: 6%), dizziness (5%; extended release capsules: 2%), fatigue (4%; extended release capsules: 2%), drowsiness (immediate and extended release: 3%), anxiety (extended release capsules: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Xeroderma (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (7%; extended release capsules: 6%), abdominal pain (5%; extended release capsules: 4%), diarrhea (4%), dyspepsia (4%; extended release capsules: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (2%; extended-release capsules: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Xerophthalmia (immediate and extended release: 3%), visual disturbance (2%; extended release capsules: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (3%), bronchitis (2%), sinusitis (extended release capsules: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, confusion, dementia (aggravated), disorientation, hallucination, memory impairment, palpitations, peripheral edema, prolonged QT interval on ECG, tachycardia</p></div>
<div class="block coi drugH1Div" id="F230049"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tolterodine or fesoterodine (both are metabolized to 5-hydroxymethyl tolterodine) or any component of the formulation; urinary retention; gastric retention; uncontrolled narrow-angle glaucoma</p></div>
<div class="block war drugH1Div" id="F230034"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Cases of angioedema have been reported; some cases have occurred after a single dose. Discontinue immediately if angioedema and associated difficulty breathing, airway obstruction, or hypotension develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause drowsiness, dizziness, and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dose reduction or discontinuation should be considered if CNS effects occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Has been associated with QTc prolongation at high (supratherapeutic) doses. The manufacturer recommends caution in patients with congenital prolonged QT or in patients receiving concurrent therapy with QTc-prolonging drugs (class Ia or III antiarrhythmics). However, the extent of QTc prolongation even at supratherapeutic dosages was less than 15 msec. Individuals who are CYP2D6 poor metabolizers or in the presence of inhibitors of CYP2D6 and CYP3A4 may be more likely to exhibit prolongation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alzheimer disease: Preliminary data suggests that long-term use of anticholinergics may potentially adversely affect the clinical course of Alzheimer disease in patients receiving cholinesterase inhibitors (Lu 2003; Sink 2008). Additional monitoring for decreases in cognition, functional abilities and increased problematic behaviors should be considered in patients with dementia receiving dual therapy with an acetylcholinesterase inhibitor and a bladder anticholinergic, such as tolterodine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bladder flow obstruction: Use with caution in patients with bladder flow obstruction (eg, benign prostatic hypertrophy); may increase the risk of urinary retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI obstructive disorders: Use with caution in patients with decreased GI motility or gastrointestinal obstructive disorders (ie, pyloric stenosis); may increase the risk of gastric retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with controlled (treated) narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment is required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP3A4 inhibitors: Dosage adjustment is recommended in patients receiving CYP3A4 inhibitors; a lower dose of tolterodine is recommended.</p></div>
<div class="block foc drugH1Div" id="F230044"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Detrol LA: 2 mg, 4 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Detrol: 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg</p></div>
<div class="block geq drugH1Div" id="F230030"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F230050"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Detrol LA Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $15.70</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $15.70</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Tolterodine Tartrate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $8.04 - $13.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $8.04 - $13.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Detrol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $9.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $9.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tolterodine Tartrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $1.00 - $3.31</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.00 - $3.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868471"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Detrol LA: 2 mg, 4 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Detrol: 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg</p></div>
<div class="block adm drugH1Div" id="F230046"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">ER capsule: Swallow whole; do not crush, chew, or open.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. IR tablet formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block admp drugH1Div" id="F52613958"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer without regard to food; do not break, crush, or chew extended-release capsules.</p></div>
<div class="block use drugH1Div" id="F230045"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">Treatment of patients with an overactive bladder with symptoms of urge urinary incontinence, urgency, or frequency</p></div>
<div class="block mst drugH1Div" id="F230107"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tolterodine may be confused with fesoterodine, tolcapone</p>
<p style="text-indent:-2em;margin-left:4em;">Detrol may be confused with Ditropan</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Tolterodine is identified in the Beers Criteria as a potentially inappropriate medication in patients 65 years and older due to its strong anticholinergic properties (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F230094"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F230039"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of Tolterodine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tolterodine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tolterodine. Management: The maximum recommended dose of tolterodine is 2 mg per day (1 mg twice daily for immediate-release tablets or 2 mg daily for extended-release capsules) when used together with a strong CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Tolterodine may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F230062"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Food increases bioavailability (~53% increase) of tolterodine tablets (dose adjustment not necessary); does not affect the pharmacokinetics of tolterodine extended release capsules. As a CYP3A4 inhibitor, grapefruit juice may increase the serum level and/or toxicity of tolterodine, but unlikely secondary to high oral bioavailability. Management: Monitor patients closely with concurrent grapefruit juice use.</p></div>
<div class="block pri drugH1Div" id="F230051"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F17917940"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tolterodine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F6712929"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Anticholinergic effects (ie, dry mouth, constipation, dizziness); renal function (BUN, creatinine); hepatic function; postvoid residual urine volume at baseline and as clinically indicated thereafter (ACOG 2015; AUA [Lerner 2021]).</p></div>
<div class="block pha drugH1Div" id="F230033"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Tolterodine is a competitive antagonist of muscarinic receptors. In animal models, tolterodine demonstrates selectivity for urinary bladder receptors over salivary receptors. Urinary bladder contraction is mediated by muscarinic receptors. Tolterodine increases residual urine volume and decreases detrusor muscle pressure.</p></div>
<div class="block phk drugH1Div" id="F230048"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Immediate release tablet: Rapid; ≥77%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: IV: V<sub>d</sub>: 113 ± 27 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &gt;96% (primarily to alpha<sub>1</sub>-acid glycoprotein) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensively hepatic, primarily via CYP2D6 to 5-hydroxymethyltolterodine (active) and 3A4 usually (minor pathway). In patients with a genetic deficiency of CYP2D6, metabolism via 3A4 predominates.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Immediate release tablet: Increased 53% with food </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Immediate release tablet: Extensive metabolizers: ~2 hours; Poor metabolizers: ~10 hours </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Extended release capsule: Extensive metabolizers: ~7 hours; Poor metabolizers: ~18 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Immediate release tablet: 1-2 hours; Extended release capsule: 2-6 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (77%); feces (17%); primarily as metabolites (&lt;1% unchanged drug) of which the active 5-hydroxymethyl metabolite accounts for 5% to 14% (&lt;1% in poor metabolizers); as unchanged drug (&lt;1%; &lt;2.5% in poor metabolizers)</p></div>
<div class="block phksp drugH1Div" id="F51204300"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with CrCl 10 to 30 mL/min, immediate-release tolterodine and metabolite levels were 2- to 3-fold higher compared with healthy patients. ER tolterodine has not been studied in patients with CrCl less than 10 mL/min.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The elimination half-life of immediate-release tolterodine was longer and Cl was substantially lower in cirrhotic patients compared with healthy patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Serum concentrations of immediate-release tolterodine and 5-HMT were 20% to 50% higher in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F230052"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Breminal | Coli Q | Detrusitol | Toltem | Urginol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodin accord | Tolterodin Actavis | Tolterodin easypharm | Tolterodin pfizer | Tolterodin ratiopharm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine tartrate</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Detrusin | Terodin | Tolorin | Tolter | Toltrex | Ucol</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Eltoven | Urostop</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bu mai ding | Detrusitol | Le zai | Ning tong | She ni ting | Si pei er | Tolterodine tartra | Tolterodine tartrate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Toldy | Tolterodina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Uroflow</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodin | Tolterodin 1A Pharma | Tolterodin accord | Tolterodin Actavis | Tolterodin Hexal | Tolterodin pfizer | Tolterodin puren | Tolterodin ratiopharm | Tolterodine aristo</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Eltoven</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Eltoven</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine accord | Uroflow</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Conturine | Cystoridine | Detrusitol | Incont | Noctopex | Sedoter | Terodine | Tolterodine | Urgeleve | Uricontrol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Urotrol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine accord</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine | Tolterodine Kent</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Detrulon | Detrusitol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Accord tolterodine | Detrusitol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine tartrate</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Concyst | Detrusitol | Roliten | Terol La | Tolter | Tolu | Torq</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Binex tolterodin er | Binex Tolterodine | Ckd tolterodine sr | Derutol sr | Deterodine sr | Detrodin sr | Detrusitol | Dirutol | Eurocarin sr | Loxirodine | Neocitol sr | Olodin sr | Sedatol | Sedatol sr | Telodin | Toladine sr | Tolersta | Toloin | Tolostar | Toltarodin | Toltedin | Toltedine | Tolten | Tolterin | Tolteros sr | Toltomin | Tt rodine sr | Uretol | Urisis | Urocarine | Urodin | Urofree | Uroq sr | Urositol | Urotin S | Urotrol | Uterodin | Uvidi</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Uroflow</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodin ratiopharm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Urodine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alarod | Asertral | Blad | Detrusitol | Dinafar | Fanerik | Ficsatol | Hipolter | Jania | Micrepis | Quimural | Tefilinb | Tolterodina | Tolterodina ultra | Ucrinix | Urotrol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow Tolterodine | Detrusitol</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Terodin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Detriflow | Detrusitol | Ezeecon | Tolcare | Toldin | Tolferid | Tolter | Uniterole</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Defur | Detrusitol | Tolterodine accord | Uroflow | Uroflow sr</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Detrol | Tolterodine tartrate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Eltoven | Tolterodina imedic | Tornade</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Uroflow</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Detruzitol | Roliten | Uroflex | Urotol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Tolterodin ebb | Tolterodin Orifarm | Tolterodin sandoz | Tolterodin teva | Tolterodine accord</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Toldin | Toltex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Terodine | Torodine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol | Roliten | Urotol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fluserin | Tolterox | Toltin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Detrusitol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tolterodine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26488524">
<a name="26488524"></a>American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 155: Urinary Incontinence in Women. <i>Obstet Gynecol</i>. 2015;126(5):e66-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tolterodine-drug-information/abstract-text/26488524/pubmed" id="26488524" target="_blank">26488524</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Detrol (tolterodine) [prescribing information]. New York, NY: Pfizer; November 2016.</div>
</li>
<li>
<div class="reference">
                  Detrol LA (tolterodine) [prescribing information]. New York, NY: Pfizer; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tolterodine-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12837675">
<a name="12837675"></a>Lu CJ, Tune LE. Chronic exposure to anticholinergic medications adversely affects the course of Alzheimer disease. <i>Am J Geriatr Psychiatry</i>. 2003;11(4):458-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tolterodine-drug-information/abstract-text/12837675/pubmed" id="12837675" target="_blank">12837675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22624162">
<a name="22624162"></a>Shamliyan T, Wyman J, Kane RL. <i>Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness</i>. Rockville (MD): Agency for Healthcare Research and Quality (US); April 2012.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tolterodine-drug-information/abstract-text/22624162/pubmed" id="22624162" target="_blank">22624162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18384584">
<a name="18384584"></a>Sink KM, Thomas J 3rd, Xu H, Craig B, Kritchevsky S, Sands LP. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. <i>J Am Geriatr Soc</i>. 2008;56(5):847-853. doi: 10.1111/j.1532-5415.2008.01681.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tolterodine-drug-information/abstract-text/18384584/pubmed" id="18384584" target="_blank">18384584</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10292 Version 445.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
